Literature DB >> 5006295

Ataxia-telangiectasia. (Clinical and immunological aspects).

E Boder, R P Sedgwick.   

Abstract

This syndrome was defined by the authors in 1947. Earlier publications of similar disease descriptions were by Syllaba and Henner (1926), Louis-Bar (1941). The authors at present have a stock of 253 cases. The cardinal symptoms of this phakomatosis are: Cerebellar ataxia which begin in infancy and take a slowly progressive course. In the late stages free walking and standing are no longer possible. Progressive atactic speech disorders, cerebellar atrophy in the pneumoencephalogram. Slowly progressing symmetrical skin and mucosal telangiectasia in the face and especially on the conjunctivae at the age of 3 to 6 years. Relapsing sinopulmonary infections with a tendency toward the development of bronchiectases. Apraxia of eye movements. Atrophy of facial skin and premature graying of hair. Recessively hereditary disorder with a high familial manifestation. This syndrome combines the spinocerebellar degeneration, phakomatoses, and infantile dementia processes. Such other conditions as abnormity or absence of thymus, reduction in gamma globulins, amino-aciduria, autosomal-recessive inheritance suggest a genetically determined "error of metabolism".

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5006295

Source DB:  PubMed          Journal:  Psychiatr Neurol Med Psychol Beih        ISSN: 0555-5469


  10 in total

1.  Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer.

Authors:  Shaun P Scott; Regina Bendix; Philip Chen; Raymond Clark; Thilo Dork; Martin F Lavin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  Effects of 4-aminopyridine on nystagmus and vestibulo-ocular reflex in ataxia-telangiectasia.

Authors:  Aasef G Shaikh; Sarah Marti; Alexander A Tarnutzer; Antonella Palla; Thomas O Crawford; David S Zee; Dominik Straumann
Journal:  J Neurol       Date:  2013-07-25       Impact factor: 4.849

Review 3.  Ataxia-telangiectasia - A historical review and a proposal for a new designation: ATM syndrome.

Authors:  Hélio A G Teive; Adriana Moro; Mariana Moscovich; Walter O Arruda; Renato P Munhoz; Salmo Raskin; Tetsuo Ashizawa
Journal:  J Neurol Sci       Date:  2015-05-29       Impact factor: 3.181

4.  Effects of antioxidants on cancer prevention and neuromotor performance in Atm deficient mice.

Authors:  Ramune Reliene; Sheila M Fleming; Marie-Françoise Chesselet; Robert H Schiestl
Journal:  Food Chem Toxicol       Date:  2007-08-29       Impact factor: 6.023

5.  Disorders of Upper Limb Movements in Ataxia-Telangiectasia.

Authors:  Aasef G Shaikh; David S Zee; Allen S Mandir; Howard M Lederman; Thomas O Crawford
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

6.  Experimental antioxidant therapy in ataxia telangiectasia.

Authors:  Ramune Reliene; Robert H Schiestl
Journal:  Clin Med Oncol       Date:  2008-05-20

Review 7.  Cell cycle control, checkpoint mechanisms, and genotoxic stress.

Authors:  R E Shackelford; W K Kaufmann; R S Paules
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

Review 8.  A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in Neurological Disorders.

Authors:  Arlene J George; Yarely C Hoffiz; Antoinette J Charles; Ying Zhu; Angela M Mabb
Journal:  Front Genet       Date:  2018-02-14       Impact factor: 4.599

9.  Newborn screening for SCID identifies patients with ataxia telangiectasia.

Authors:  Jacob Mallott; Antonia Kwan; Joseph Church; Diana Gonzalez-Espinosa; Fred Lorey; Ling Fung Tang; Uma Sunderam; Sadhna Rana; Rajgopal Srinivasan; Steven E Brenner; Jennifer Puck
Journal:  J Clin Immunol       Date:  2012-12-20       Impact factor: 8.317

10.  Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence.

Authors:  Hege Edvardsen; Toril Tefre; Laila Jansen; Phuong Vu; Bruce G Haffty; Sophie D Fosså; Vessela N Kristensen; Anne-Lise Børresen-Dale
Journal:  Radiat Oncol       Date:  2007-07-10       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.